SEC Form 4 · accession 0001159036-15-000034
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David A Ramsay
Officer — VP and Chief Financial Officer
Period of report
Feb 4, 2015
Accepted (ET)
Feb 6, 2015 · 7:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 6, 2015 | M | 7,088 | $0.00 | A | 366,980 | D | |
| Common StockF1 | Feb 6, 2015 | F | 2,660 | $13.87 | D | 364,320 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $13.81 | Feb 4, 2015 | A | 45,000 | A | Feb 4, 2016 | Feb 4, 2025 | Common Stock | 45,000 | 45,000 | D |
| Restricted Stock UnitsF3 | $0.00 | Feb 4, 2015 | A | 28,000 | A | Feb 4, 2016 | Feb 4, 2025 | Common Stock | 28,000 | 28,000 | D |
| Restricted Stock Units | $0.00 | Feb 6, 2015 | M | 7,088 | D | Feb 6, 2015 | Feb 6, 2024 | Common Stock | 7,088 | 21,262 | D |
Explanation of responses
- F1The reported disposition of 2,660 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding requirements.
- F2This option vests one-fourth on such date and then 1/48 monthly thereafter.
- F3This award vests one-fourth on such date and then one-fourth on each anniversary thereafter.